
Neurolutions and Kandu Health today announced a strategic partnership that will see Kandu’s expert clinicians support Neurolutions by providing clinical consultation and assessments of stroke survivors to determine patients who may benefit from Neurolution’s IpsiHand System.
Kandu Health provides remote, multidisciplinary support to stroke survivors and care partners after hospital discharge through a team of clinically licensed navigators and an app. The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits.
The IpsiHand System is a breakthrough therapeutic device in neurorehabilitation that uses brain-computer interface technology developed for chronic stroke patients with an impaired upper extremity to help regain function after stroke.
“The Neurolutions IpsiHand is a next-generation solution that meets stroke survivors where they are and empowers them through advanced thought-driven neurotechnology. By partnering with Kandu Health, we can ensure that individuals who most need the IpsiHand System are able to get it in a timely manner, and with the critical clinical support needed to optimize patient care,” said Leo Petrossian, CEO of Neurolutions, Inc. “We believe this will significantly expedite the recovery journey for countless stroke survivors.”
Kandu Health’s expertise in creating tech-enabled solutions for stroke recovery is a strong complement to Neurolutions’ IpsiHand System. Kandu Health’s integrated approach ensures that stroke survivors, clinicians, and care partners are connected, supported, and equipped with the resources throughout the recovery process.
“By combining our educational and clinical support with Neurolutions’ technology, we are taking a critical step forward in the way we approach and manage stroke recovery; allowing access and engagement from the comfort of a patient’s own home,” said Kirsten Carroll, CEO of Kandu Health. “This partnership is poised to offer patients an unprecedented level of care and support during an immensely vulnerable time of life.”